Edmund Harrigan - Net Worth and Insider Trading
Edmund Harrigan Net Worth
The estimated net worth of Edmund Harrigan is at least $10 Million dollars as of 2023-03-28. Edmund Harrigan is the Director of Karuna Therapeutics Inc and owns about 55,163 shares of Karuna Therapeutics Inc (KRTX) stock worth over $10 Million. Edmund Harrigan is the Director of ACADIA Pharmaceuticals Inc and owns about 1,000 shares of ACADIA Pharmaceuticals Inc (ACAD) stock worth over $18,430. Edmund Harrigan is also the Director of PhaseBio Pharmaceuticals Inc and owns about 6,000 shares of PhaseBio Pharmaceuticals Inc (PHASQ) stock worth over $5. Details can be seen in Edmund Harrigan's Latest Holdings Summary section.
Transaction Summary of Edmund Harrigan
Edmund Harrigan Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Edmund Harrigan owns 5 companies in total, including Incyte Corp (INCY) , Karuna Therapeutics Inc (KRTX) , and ACADIA Pharmaceuticals Inc (ACAD) among others .
Click here to see the complete history of Edmund Harrigan’s form 4 insider trades.
Insider Ownership Summary of Edmund Harrigan
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| INCY | Incyte Corp | 2019-12-16 | director |
| KRTX | Karuna Therapeutics Inc | 2019-06-27 | director |
| ACAD | ACADIA Pharmaceuticals Inc | 2019-06-26 | director |
| PHASQ | PhaseBio Pharmaceuticals Inc | 2020-06-03 | director |
| BLCM | Bellicum Pharmaceuticals Inc | 2018-02-20 | director |
Edmund Harrigan Latest Holdings Summary
Edmund Harrigan currently owns a total of 3 stocks. Among these stocks, Edmund Harrigan owns 55,163 shares of Karuna Therapeutics Inc (KRTX) as of August 12, 2020, with a value of $10 Million and a weighting of 99.81%. Edmund Harrigan owns 1,000 shares of ACADIA Pharmaceuticals Inc (ACAD) as of August 16, 2016, with a value of $18,430 and a weighting of 0.19%. Edmund Harrigan also owns 6,000 shares of PhaseBio Pharmaceuticals Inc (PHASQ) as of December 3, 2020, with a value of $5 and a weighting of 0%.
Latest Holdings of Edmund Harrigan
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| KRTX | Karuna Therapeutics Inc | 2020-08-12 | 55,163 | 180.05 | 9,932,098 |
| ACAD | ACADIA Pharmaceuticals Inc | 2016-08-16 | 1,000 | 18.43 | 18,430 |
| PHASQ | PhaseBio Pharmaceuticals Inc | 2020-12-03 | 6,000 | 0.00 | 5 |
Holding Weightings of Edmund Harrigan
Edmund Harrigan Form 4 Trading Tracker
According to the SEC Form 4 filings, Edmund Harrigan has made a total of 3 transactions in Karuna Therapeutics Inc (KRTX) over the past 5 years, including 0 buys and 3 sells. The most-recent trade in Karuna Therapeutics Inc is the sale of 10,000 shares on August 12, 2020, which brought Edmund Harrigan around $833,200.
According to the SEC Form 4 filings, Edmund Harrigan has made a total of 0 transactions in ACADIA Pharmaceuticals Inc (ACAD) over the past 5 years. The most-recent trade in ACADIA Pharmaceuticals Inc is the acquisition of 1,000 shares on August 16, 2016, which cost Edmund Harrigan around $32,970.
According to the SEC Form 4 filings, Edmund Harrigan has made a total of 1 transactions in PhaseBio Pharmaceuticals Inc (PHASQ) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in PhaseBio Pharmaceuticals Inc is the acquisition of 6,000 shares on December 3, 2020, which cost Edmund Harrigan around $24,720.
Insider Trading History of Edmund Harrigan
- 1
Edmund Harrigan Trading Performance
GuruFocus tracks the stock performance after each of Edmund Harrigan's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Edmund Harrigan is -10.06%. GuruFocus also compares Edmund Harrigan's trading performance to market benchmark return within the same time period. The performance of stocks bought by Edmund Harrigan within 3 months outperforms 0 times out of 2 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Edmund Harrigan's insider trading performs compared to the benchmark.
Performance of Edmund Harrigan
Average Relative Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Relative Return(%) | -6.18 | -10.06 | 3.74 | -27.68 | -62.47 | -2.93 |
| Relative Return to S&P 500(%) | -6.5 | -12.11 | -7.32 | -46.22 | -72.26 | -12.8 |
Edmund Harrigan Ownership Network
Ownership Network List of Edmund Harrigan
Ownership Network Relation of Edmund Harrigan
Edmund Harrigan Owned Company Details
What does Incyte Corp do?
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Who are the key executives at Incyte Corp?
Edmund Harrigan is the director of Incyte Corp. Other key executives at Incyte Corp include Principal Accounting Officer Thomas Tray , EVP & Head of Tech. Operations Michael James Morrissey , and EVP & General Manager & Europe Jonathan Elliott Dickinson .
Incyte Corp (INCY) Insider Trades Summary
Over the past 18 months, Edmund Harrigan made no insider transaction in Incyte Corp (INCY). Other recent insider transactions involving Incyte Corp (INCY) include a net purchase of 2,510,403 shares made by Baker Bros. Advisors Lp , a net sale of 30,111 shares made by Vijay K Iyengar , and a net sale of 46,866 shares made by Barry P Flannelly .
In summary, during the past 3 months, insiders sold 97,842 shares of Incyte Corp (INCY) in total and bought 0 shares, with a net sale of 97,842 shares. During the past 18 months, 209,240 shares of Incyte Corp (INCY) were sold and 2,510,403 shares were bought by its insiders, resulting in a net purchase of 2,301,163 shares.
Incyte Corp (INCY)'s detailed insider trading history can be found in Insider Trading Tracker table.
Incyte Corp Insider Transactions
Edmund Harrigan Mailing Address
Above is the net worth, insider trading, and ownership report for Edmund Harrigan. Currently GuruFocus does not have mailing address information for Edmund Harrigan.
